Risks of infection and severity of coronavirus disease 2019 in kidney transplant recipients: A single-center cohort study
CONCLUSION: In kidney transplant recipients, the infection rate and severity of COVID-19 tended to increase with higher maintenance doses of steroids. Recipients taking >5 mg of prednisolone should be considered a switch from tacrolimus to cyclosporine because cyclosporine may inhibit viral replication and reduce the risk of infection.PMID:38452985 | DOI:10.1016/j.trim.2024.102023 (Source: Transplant Immunology)
Source: Transplant Immunology - March 7, 2024 Category: Transplant Surgery Authors: Kuniaki Inoue Shunta Hori Mitsuru Tomizawa Tatsuo Yoneda Yasushi Nakai Makito Miyake Nobumichi Tanaka Kiyohide Fujimoto Source Type: research
Risks of infection and severity of coronavirus disease 2019 in kidney transplant recipients: A single-center cohort study
CONCLUSION: In kidney transplant recipients, the infection rate and severity of COVID-19 tended to increase with higher maintenance doses of steroids. Recipients taking >5 mg of prednisolone should be considered a switch from tacrolimus to cyclosporine because cyclosporine may inhibit viral replication and reduce the risk of infection.PMID:38452985 | DOI:10.1016/j.trim.2024.102023 (Source: Transplant Immunology)
Source: Transplant Immunology - March 7, 2024 Category: Transplant Surgery Authors: Kuniaki Inoue Shunta Hori Mitsuru Tomizawa Tatsuo Yoneda Yasushi Nakai Makito Miyake Nobumichi Tanaka Kiyohide Fujimoto Source Type: research
Risks of infection and severity of coronavirus disease 2019 in kidney transplant recipients: A single-center cohort study
CONCLUSION: In kidney transplant recipients, the infection rate and severity of COVID-19 tended to increase with higher maintenance doses of steroids. Recipients taking >5 mg of prednisolone should be considered a switch from tacrolimus to cyclosporine because cyclosporine may inhibit viral replication and reduce the risk of infection.PMID:38452985 | DOI:10.1016/j.trim.2024.102023 (Source: Transplant Immunology)
Source: Transplant Immunology - March 7, 2024 Category: Transplant Surgery Authors: Kuniaki Inoue Shunta Hori Mitsuru Tomizawa Tatsuo Yoneda Yasushi Nakai Makito Miyake Nobumichi Tanaka Kiyohide Fujimoto Source Type: research
Risks of infection and severity of coronavirus disease 2019 in kidney transplant recipients: A single-center cohort study
CONCLUSION: In kidney transplant recipients, the infection rate and severity of COVID-19 tended to increase with higher maintenance doses of steroids. Recipients taking >5 mg of prednisolone should be considered a switch from tacrolimus to cyclosporine because cyclosporine may inhibit viral replication and reduce the risk of infection.PMID:38452985 | DOI:10.1016/j.trim.2024.102023 (Source: Transplant Immunology)
Source: Transplant Immunology - March 7, 2024 Category: Transplant Surgery Authors: Kuniaki Inoue Shunta Hori Mitsuru Tomizawa Tatsuo Yoneda Yasushi Nakai Makito Miyake Nobumichi Tanaka Kiyohide Fujimoto Source Type: research
Risks of infection and severity of coronavirus disease 2019 in kidney transplant recipients: A single-center cohort study
CONCLUSION: In kidney transplant recipients, the infection rate and severity of COVID-19 tended to increase with higher maintenance doses of steroids. Recipients taking >5 mg of prednisolone should be considered a switch from tacrolimus to cyclosporine because cyclosporine may inhibit viral replication and reduce the risk of infection.PMID:38452985 | DOI:10.1016/j.trim.2024.102023 (Source: Transplant Immunology)
Source: Transplant Immunology - March 7, 2024 Category: Transplant Surgery Authors: Kuniaki Inoue Shunta Hori Mitsuru Tomizawa Tatsuo Yoneda Yasushi Nakai Makito Miyake Nobumichi Tanaka Kiyohide Fujimoto Source Type: research
Two acute kidney injury episodes after ICI therapy: a case report
AbstractA 74-year-old Japanese male with lung squamous cell carcinoma received his first dose of immune checkpoint inhibitors (ICIs): ipilimumab and nivolumab. He developed acute kidney injury (AKI) and was admitted to our department. We diagnosed kidney immune-related adverse effects (irAE), and a kidney biopsy revealed acute tubulointerstitial nephritis. We started oral prednisolone (PSL) and his AKI immediately improved. The patient maintained stable findings after PSL was tapered off. However, seven months after the ICI administration, he developed rapid progressive glomerular nephritis and was admitted to our departme...
Source: CEN Case Reports - March 7, 2024 Category: Urology & Nephrology Source Type: research
Case report: Sustained complete remission with all-oral MEPED therapy in a patient with Hodgkin's disease developing resistance to pembrolizumab
In conclusion, we demonstrate for the first time that MEPED therapy is highly effective in a patient with Hodgkin's disease who has been refractory to ICPi. Sustained CR was achieved over 11 months after initiation of MEPED therapy. Further studies on a larger patient cohort should be performed.PMID:38444946 | PMC:PMC10912635 | DOI:10.3389/fphar.2024.1334233 (Source: Cancer Control)
Source: Cancer Control - March 6, 2024 Category: Cancer & Oncology Authors: K Reuthner P Aubele K Menhart P Rath D C Harrer W Herr J Hahn M Vogelhuber D Heudobler F Lueke A Reichle M Grube Source Type: research
Glucocorticoid discontinuation rate and risk factors for relapses in a contemporary cohort of patients with giant cell arteritis
AbstractThe rates of relapses and therapy discontinuation in patients with giant cell arteritis (GCA) in the modern therapeutic era have not been defined. We aimed to evaluate the glucocorticoid (GC) discontinuation rate and the factors associated with relapses in a contemporary GCA cohort. Patient and treatment data were collected cross-sectionally at first evaluation and 2 years later (second evaluation), in a multicenter, prospective GCA cohort. Predictors of relapses were identified by logistic regression analyses. 243 patients with GCA were initially included (67% women, mean age at diagnosis: 72.1 years, median disea...
Source: Rheumatology International - March 5, 2024 Category: Rheumatology Source Type: research
Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation
CONCLUSIONS: The RS-DAT met BE criteria (range 80%-125%) versus SAC based on 90% CI of GMR for Cmax,ss and AUC 0-24h,ss. The LS-DAT was considered BE to SAC on the basis of the niraparib component meeting the BE criteria in the primary analysis for AUC 0-72h; abiraterone meeting the BE criteria in additional paired analyses based on Cmax,ss and AUC 0-24h,ss; and the percentage of simulated LS-DAT versus SAC BE trials meeting the BE criteria for both.GOV IDENTIFIER: NCT04577833.PMID:38436924 | DOI:10.1007/s40262-023-01340-5 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 4, 2024 Category: Cancer & Oncology Authors: Alex Yu Anasuya Hazra James Juhui Jiao Peter Hellemans Anna Mitselos Hui Tian Juan Jose Perez Ruixo Nahor Haddish-Berhane Daniele Ouellet Alberto Russu Source Type: research
Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation
CONCLUSIONS: The RS-DAT met BE criteria (range 80%-125%) versus SAC based on 90% CI of GMR for Cmax,ss and AUC 0-24h,ss. The LS-DAT was considered BE to SAC on the basis of the niraparib component meeting the BE criteria in the primary analysis for AUC 0-72h; abiraterone meeting the BE criteria in additional paired analyses based on Cmax,ss and AUC 0-24h,ss; and the percentage of simulated LS-DAT versus SAC BE trials meeting the BE criteria for both.GOV IDENTIFIER: NCT04577833.PMID:38436924 | DOI:10.1007/s40262-023-01340-5 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 4, 2024 Category: Cancer & Oncology Authors: Alex Yu Anasuya Hazra James Juhui Jiao Peter Hellemans Anna Mitselos Hui Tian Juan Jose Perez Ruixo Nahor Haddish-Berhane Daniele Ouellet Alberto Russu Source Type: research
Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation
ConclusionsThe RS-DAT met BE criteria (range 80% –125%) versus SAC based on 90% CI of GMR for Cmax,ss and AUC0 –24h,ss. The
LS-DAT was considered BE to SAC on the basis of the niraparib component meeting the BE criteria in the primary analysis for AUC0 –72h; abiraterone meeting the BE criteria in additional paired analyses based on Cmax,ss and AUC0 –24h,ss; and the percentage of
simulated LS-DAT versus SAC BE trials meeting the BE criteria for both.ClinicalTrials.gov IdentifierNCT04577833.Graphical Abstract (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - March 4, 2024 Category: Drugs & Pharmacology Source Type: research
Cytokine Release Syndrome with Relative Adrenal Insufficiency Induced by Ipilimumab and Nivolumab Combination Therapy for Clear Cell Renal Cell Carcinoma
Intern Med. 2024 Mar 4. doi: 10.2169/internalmedicine.3115-23. Online ahead of print.ABSTRACTCombination therapy with ipilimumab and nivolumab is indicated for many types of cancers; however, several patients experience immune-related adverse events (irAEs). We herein report a case of cytokine release syndrome (CRS) in a 63-year-old woman with stage IV left clear cell renal cell carcinoma. Our patient developed CRS while taking prednisolone, 43 days after the start of ipilimumab and nivolumab administration. The patient was treated with steroid pulse therapy, which improved the symptoms of shock and respiratory failure. In...
Source: Internal Medicine - March 3, 2024 Category: Internal Medicine Authors: Kohei Yamamoto Shinsuke Shiotsu Misaki Sasakura Shunya Tanaka Shiho Goda Taisuke Tsuji Tatsuya Yuba Chieko Takumi Noriya Hiraoka Source Type: research
